Shruti Murali, MD
Medical Oncology · Towson, MDNPI 1902241649
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 9.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for medical oncology clinicians in MD, where the typical reported total is $4,199.
Across 137 payments — averaging $30.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$380
- Pfizer$344
- Novartis$295
- GSK$279
- AstraZeneca$277
- Exelixis Inc.$186
- plus $2K from 31 others
Across 26 payments — averaging $596.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ares Trading SA$16K
What the payments were for
- Food & beverage$4,10798%
- Education$922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 6 | $380 |
| Pfizer | 14 | $344 |
| Novartis | 11 | $295 |
| GSK | 9 | $279 |
| AstraZeneca(2 entities) | 8 | $277 |
| Exelixis Inc. | 4 | $186 |
| Johnson & Johnson | 7 | $160 |
| E.r. Squibb & Sons, L.L.C. | 6 | $157 |
| Caris MPI, Inc. | 3 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $139 |
| AbbVie | 5 | $135 |
| Incyte Corporation | 6 | $128 |
| Bristol Myers Squibb | 4 | $123 |
| Lilly USA, LLC | 2 | $122 |
| Intera Oncology, Inc | 1 | $114 |
| Daiichi Sankyo Inc. | 4 | $113 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $110 |
| Merck | 4 | $107 |
| Seagen Inc. | 4 | $94 |
| Puma Biotechnology, Inc. | 5 | $89 |
| Mirati Therapeutics, Inc. | 3 | $86 |
| Regeneron Healthcare Solutions, Inc. | 3 | $75 |
| Gilead | 4 | $74 |
| Array Biopharma Inc | 3 | $73 |
| Astellas Pharma US Inc | 2 | $57 |
| Beigene USA, Inc. | 2 | $49 |
| Stemline Therapeutics Inc. | 2 | $39 |
| Pharmaessentia USA Corporation | 1 | $32 |
| Eisai Inc. | 1 | $30 |
| Tempus AI, Inc | 1 | $29 |
| Sobi, Inc | 1 | $28 |
| Coherus Oncology, Inc. | 1 | $26 |
| Spectrum Pharmaceuticals Inc. | 1 | $22 |
| Sanofi | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Acrotech Biopharma Inc. | 1 | $15 |
| Deciphera Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,199 in reported general payments places this provider in the 50th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 32 | $464,869 |
| InlytaAxitinib | 21 | $373,291 |
| XtandiEnzalutamide | 20 | $366,276 |
| ErleadaApalutamide | 12 | $173,951 |
| NubeqaDarolutamide | 12 | $153,639 |
| BrukinsaZanubrutinib | 14 | $124,789 |
| Lenalidomide | 13 | $107,785 |
| Abiraterone Acetate | 43 | $63,045 |
| EliquisApixaban | 38 | $26,538 |
| XareltoRivaroxaban | 23 | $26,436 |
| Letrozole | 57 | $2,195 |
| Anastrozole | 66 | $1,723 |
| Prednisone | 86 | $502 |
| Pregabalin | 11 | $456 |
| Hydroxyurea | 20 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $277 | $464,86932 claims |
| PfizerInlyta, Eliquis | $344 | $399,82859 claims |
| Astellas Pharma US IncXtandi | $57 | $366,27620 claims |
| Johnson & JohnsonErleada, Xarelto | $160 | $200,38635 claims |
| Beigene USA, Inc.Brukinsa | $49 | $124,78914 claims |
| Lilly USA, LLCOlanzapine | $122 | $4911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 180 medical oncology providers in Maryland.
Other medical oncology in Towson
- Mario EisenbergerBaltimore$2.9M
- Adrian SenderowiczBethesda$1.6M
- Mohit NarangOwing Mills$1.3M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.